Kastelein, J. J. P., Hovingh, G. K., Langslet, G., Baccara-Dinet, M. T., Gipe, D. A., Chaudhari, U., … Farnier, M. (2017). Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 11(1), 195-203.e4. https://doi.org/10.1016/j.jacl.2016.12.004

Kastelein, John J. P., G Kees Hovingh, Gisle Langslet, Marie T. Baccara-Dinet, Daniel A. Gipe, Umesh Chaudhari, Jian Zhao, Pascal Minini, and Michel Farnier. “Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.” Journal of Clinical Lipidology 11, no. 1 (January 2017): 195-203.e4. https://doi.org/10.1016/j.jacl.2016.12.004.

Kastelein JJP, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology. 2017 Jan;11(1):195-203.e4.

Kastelein, John J. P., et al. “Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.” Journal of Clinical Lipidology, vol. 11, no. 1, Elsevier BV, Jan. 2017, pp. 195-203.e4. Crossref, doi:10.1016/j.jacl.2016.12.004.

Kastelein JJP, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology. Elsevier BV; 2017 Jan;11(1):195-203.e4.